<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141486</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Current controversies in glycemic control targets. What do the results of the latest clinical trials tell us about the approach to type 2 diabetes mellitus?</dc:title>
<dc:description xml:lang="en">The aim of this article is to discuss the implications of the results obtained in the latest large-scale clinical trials designed to evaluate the effect of intensive glycemic control on the vascular complications associated with type 2 diabetes mellitus. The current scientific evidence is reviewed and the implications of the ACCORD (The Action to Control Cardiovascular Risk in Diabetes study group), ADVANCE (Action in Diabetes and Vascular disease: Preterax and Diamicron Modified Release Control Evaluation) and VADT (Veterans Affairs Diabetes Trial) clinical trials are discussed. General concerns of the studies and their implications for clinical practice and the management of type 2 diabetes, as well as the questions which still need to be answered by future clinical research are discussed (AU)</dc:description>
<dc:creator>Rius, Ferran</dc:creator>
<dc:creator>Mauricio, Dídac</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El objetivo de este artículo consiste en realizar una reflexión sobre las implicaciones de los resultados obtenidos en los últimos grandes ensayos clínicos planteados para evaluar el efecto del control glucémico intensivo sobre las complicaciones vasculares asociadas a la diabetes mellitus tipo 2. Se revisa la evidencia científica previa y se discuten las implicaciones de los ensayos clínicos ACCORD (The Action to Control Cardiovascular Risk in Diabetes study group), ADVANCE (Action in Diabetes and Vascular disease: Preterax and Diamicron modified realease Control Evaluation) y VADT (Veterans Affairs Diabetes Trial). Se comentan, además, los aspectos generales de los estudios y su implicación tanto para la práctica clínica en el tratamiento de la diabetes tipo 2 como las cuestiones por responder a través de la investigación clínica en el futuro (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);135(supl.2): 2-5, sept. 2010. tab</dc:source>
<dc:identifier>ibc-141486</dc:identifier>
<dc:title xml:lang="es">Controversias actuales en los objetivos de control glucémico. ¿Qué reflexiones exigen los resultados de los últimos estudios para abordar la diabetes mellitus tipo 2?</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d3946^s22057</dc:subject>
<dc:subject>^d1812</dc:subject>
<dc:subject>^d3946^s22012</dc:subject>
<dc:subject>^d2359^s22054</dc:subject>
<dc:subject>^d3946^s22062</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7182^s22073</dc:subject>
<dc:subject>^d2359^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201009</dc:date>
</metadata>
</record>
</ibecs-document>
